BiotechReporter staff
Milestone Pharmaceuticals (Nasdaq:MIST) is accelerating development of its lead cardiovascular therapy after securing $125 million in funding from RTW Investments and other backers.
The Montreal-based biotech is developing small-molecule therapeutics for transient cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). The company says the capital will support Phase 3 clinical trials and regulatory submissions in both Canada and the United States.
Milestone’s approach targets rapid symptom relief without invasive procedures, offering a potential breakthrough for emergency and outpatient care. Analysts say the investment reflects growing confidence in Canada’s clinical pipeline and the global demand for non-invasive cardiac therapies.
The company plans to begin trial expansion later this quarter, with results expected to inform final approval pathways.
